Epigenome editing based treatment: Progresses and challenges
Molecular Therapy · 2026-01 · 34 (1) · 46-67
DOI: 10.1016/j.ymthe.2025.08.047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2026-01. Verfasst von Luowei Yuan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Health Sciences, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China. Hauptthemen laut MEDLINE: Gene Editing, Epigenome, Epigenesis, Genetic, Genetic Therapy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Science and Technology Innovation Commission, Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Epigenome editing is emerging as a transformative approach in clinical treatment, enabling precise modifications to gene expression without altering the underlying DNA sequence. The ongoing transition of epigenome editing techniques from foundational research to clinical applications highlights several key strategies. These include targeted DNA methylation/demethylation, histone modification, and transcriptional regulation. These approaches offer the potential for durable and reversible gene expression modulation, paving the way for precisely tailored therapies for genetic and complex diseases. Here, we review pioneering research, technological advancements, granted patents, and clinical trials that have been reported during the past decade. By synthesizing current research and development efforts, this review aims to provide insights into the promising landscape of epigenome editing and its potential to promote therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Biomedical Health Sciences, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Division of Biomedical Health Sciences, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China; Ciechanover Institute of Precision and Regenerative Medicine, The Chinese University of Hong Kong,…
Förderung
- Shenzhen Science and Technology Innovation Commission
- Shenzhen Science and Technology Innovation Program
- National Natural Science Foundation of China
Zitieren
APA
Yuan, L., Xiong, Y., Zhang, Y., Gu, S., & Lei, Y. (2026). Epigenome editing based treatment: Progresses and challenges. Molecular Therapy, 34(1), 46-67. https://doi.org/10.1016/j.ymthe.2025.08.047
Vancouver
Yuan L, Xiong Y, Zhang Y, Gu S, Lei Y. Epigenome editing based treatment: Progresses and challenges. Molecular Therapy. 2026;34(1):46-67. doi:10.1016/j.ymthe.2025.08.047
BibTeX
@article{Yuan2026,
author = {Yuan, Luowei and Xiong, Yikai and Zhang, Yiming and Gu, Shen and Lei, Yong},
title = {Epigenome editing based treatment: Progresses and challenges},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {1},
pages = {46--67},
doi = {10.1016/j.ymthe.2025.08.047}
}
EUVIMED